FDA Renews Compounding Advisory Committee

[membership level=”0,4″][The content continues for paid members only.] Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership] In early May 2016, FDA announced its intention to renew the Pharmacy Compounding Advisory Committee for an additional two years. The committee was established to provide advice to the Commissioner of Food and Drugs on scientific, technical, and medical issues concerning drug compounding. The committee’s next quarterly meeting will be held on June 23 at the FDA White Oak campus to discuss six additional bulk drug substances nominated for the 503A bulk drug substances list and to receive up- dates on various issues brought up at previous meetings.
[/membership]